DiaMedica Therapeutics (DMAC) Operating Expenses (2018 - 2026)

DiaMedica Therapeutics' Operating Expenses history runs 9 years deep, the most recent figure standing at $10.5 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 28.71% year-over-year to $10.5 million in Q1 2026; TTM through Mar 2026 was $36.7 million, a 26.31% increase from a year earlier, with the FY2025 full-year figure at $34.4 million, up 28.92% from the prior year.
• Operating Expenses climbed to $10.5 million in Q1 2026 per DMAC's latest filing, from $9.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $10.5 million in Q1 2026 and bottomed at $3.1 million in Q3 2022.
• The 5-year median for Operating Expenses is $5.7 million (2024), against an average of $6.3 million.
• Across the five-year window, Operating Expenses decreased 8.43% in 2022 and jumped 64.87% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $4.0 million in 2022, then surged by 47.19% to $5.8 million in 2023, then jumped by 43.96% to $8.4 million in 2024, then gained by 9.43% to $9.2 million in 2025, then increased by 13.77% to $10.5 million in 2026.
• Per Business Quant, the three latest DMAC Operating Expenses figures stand at $10.5 million (Q1 2026), $9.2 million (Q4 2025), and $9.0 million (Q3 2025).